Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 6017

Gilead's herpes deal; FDA approvals for Boehringer, Roche

$
0
0
Plus, news about BioMarin and Cassava. 💊 Gilead opts into Assembly Bio’s genital herpes programs: As a result, Gilead will pay Assembly $35 million based on a 2023 deal. The decision comes after Assembly ...

Viewing all articles
Browse latest Browse all 6017

Trending Articles